London Puts the Spotlight on Cord Blood

London Puts the Spotlight on Cord Blood

cord blood spotlight london fact cba isct meetingsLondon is buzzing with talk about cord blood these days!  The 2017 ISCT Meetings kicked off last week with a 2-day focus on cord blood featuring experts from FACT, CBA, ISCT and ASBMT.  Our team was fortunate to be in attendance for this exclusive event.

The first day of the event focused on introducing banks to the FACT Cord Blood inspection process as well as the need for international standards. A portion of the day was also dedicated to explaining the role of the inspector and the requirements for becoming an inspector.

On the second day, meetings ran in tandem featuring a variety of topics and speakers. Attendees were encouraged to float between the two rooms and attend those meeting most important to them. In one room, FACT focused on real world applications of procedures and concepts. The day was designed to strengthen attendees quality assurance knowledge through a variety of presentations and exercises.

One of our favorite presentations and exercises looked at the implications and risks of having standards that are too strict given the potential new applications for cord blood in the near future. This topic was led by Ed Brindle, MSc, MLT from Insception Lifebank cord blood bank in Canada and an active volunteer on the FACT Accreditation Standards Committee.  He challenged attendees to work together to determine the pros and cons of changing certain acceptance criteria for cord blood units and the impact that these changes would have on current and future therapies.

Another notable presentation was made by Gesine Koegler, PhD who discussed the recent evolutions in the industry, namely the NetCord and WMDA partnership. Not only did Koegler give an overview of current trends in the industry but she spoke in great detail about the benefits of bringing WMDA and NetCord together under one umbrella. Born out of common goals, the new partnership signals another milestone for the industry as a whole.

CBA Agenda ISCT 2017

CBA Agenda ISCT 2017

Just upstairs, the Cord Blood Association together with ISCT and ABSMT held a full day of presentations. They hosted a truly dynamic group of speakers including Jaap Boelens, PhD. and Juliet Barker, MBBS. Dr. Joanne Kurtzberg and Dr. Elizabeth J. Shpall presented alongside key leaders in the field to cover topics such as cord expansion, cord blood versus haplo trends and breakthroughs in regenerative medicine. Each presentation was packed with useful information and the question/answer sessions were particularly beneficial.

Without a doubt the 2-day Cord Blood Spotlight was both highly educational and practical. As attendees, we learned about the importance of international standards for both public and private cord blood banks. We also enjoyed hearing how the latest research is advancing and then going back to the workshops to explore how the standards might change in the future based on these developments.

One thing is clear. . . the best public/private cord blood banks understand these details. They are actively making sure that the cord blood units they store are accessible and usable for current applications. They are also preparing today for what the near future holds, especially with regards to regenerative medicine.

 

Habla espanol ? Discover our selection of articles in Spanish.

medicina regerativa cordon umbilical

 

 

 

“Medicina regenerativa:
Salve vidas y reduzca costos de atención médica”

 

 

Share the Science: Dr. Tim Nelson from the MAYO Clinic, Strengthening the HLHS Heart with Cord Blood

Share the Science: Dr. Tim Nelson from the MAYO Clinic, Strengthening the HLHS Heart with Cord Blood

Cutting edge research at the MAYO Clinic is leading to new hope for individuals with HLHS Heart Syndrome and cord blood is a critical part of the story. Can cord blood strengthen the heart?  Dr. Timothy Nelson recently discussed his latest clinical trial on “Share the Science.”

Update: Dr. Nelson made his presentation live on “Share the Science” on May 17th, 2017. The recording is now available for viewing. Please click below.

Free Webinar: Save the Cord Foundation and Mediware, Inc. are proud to welcome Dr. Timothy Nelson for our next edition of Share the Science on May 17th, 2017. Share the Science is a free webinar series focused on the cord blood industry and the latest research in this field.  As always, we invite both health professionals and the general public to join us for this enlightening presentation.

Imagine the news. . . you are pregnant or perhaps just gave birth and your doctor tells you that your baby’s heart has not developed correctly. It is HLHS. Treatment typically involves a series of three intense surgeries as soon as the baby is born. If left untreated, HLHS is fatal soon after birth.

What is HLHS?

HLHS or Hypoplastic Left Heart Syndrome is a rare and complex congenital heart defect for which there is currently no cure.  Affecting more than 2,000 newborns in the United States each year, this disease is defined by underdevelopment.  According to the Mayo Clinic, “In HLHS, the left side of a child’s heart — the left ventricle, ascending aorta and left heart valves — is severely underdeveloped. The result is a heart with only a single functional ventricular chamber — the right ventricle — and a small ascending aorta.” (Source: Mayo Foundation for Medical Education and Research (MFMER))

At the MAYO Clinic, Dr. Timothy Nelson, M.D., Ph.D. leads an innovative team of physicians and scientists with one goal in mind. . . find a cure for HLHS.  As the director of Mayo Clinic’s Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome, and the the medical director of the Regenerative Medicine Consult Service, Dr. Nelson and his team are pursuing an innovative clinical trial using stem cells from cord blood to strengthen a baby’s heart following a HLHS diagnosis. The umbilical cord blood cells are processed in a specific manner in order to create highly concentrated stem cells that are injected into the heart at the time of the baby’s second open heart surgery.

The HLHS program has also recently created the HLHS consortium, a network of institutions that are participating in HLHS research. The consortium makes it easier for patients to participate in the overall research, including the umbilical cord blood collection, no matter their location.

Join us for this special presentation. . .

Dr. Timothy NELSON
from the Mayo Clinic’s
Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome

“Strengthening the HLHS Heart Using Umbilical Cord Blood”

Wednesday, May 17 | 2 p.m. – 3 p.m. Central Time

Free to register. Open to the public.

View the recording of SHARE THE SCIENCE with Dr. Timothy Nelson – Strengthening the HLHS Heart Using Umbilical Cord Blood

In this webinar, you will learn:

  • The importance of banking umbilical cord blood for babies with HLHS
  • What makes Mayo Clinic’s Todd and Karen Wanek Family Program for HLHS unique when it comes to umbilical cord blood banking
  • Details about the clinical trial using umbilical cord blood for babies with HLHS
  • How HLHS research at Mayo Clinic’s HLHS program is changing the future for HLHS individuals

 

Want to learn more?

Share the Science continues to be a popular series within the cord blood community and beyond. We welcome your input on the series and suggestions for future speakers. Give your feedback here.

powerhouses of science - cord blood research
Previous Share the Science presentations have been archived for your reference. Discover the work of leading scientists and cord blood industry experts through this educational series. View the archive now.

Share the Science is made possible thanks to the generous support of Mediware, Inc.

 

Share the Science: Dr. Moshe Israeli – Role of Cord Blood in Stem Cell Donor Search

Share the Science: Dr. Moshe Israeli – Role of Cord Blood in Stem Cell Donor Search

Register now to hear Dr. Moshe Israeli, director of the tissue typing laboratory at Rabin Medical Center in Israel, discuss the fascinating clinical world of immunogenetics and the role of cord blood in stem cell donor searches.

Save the Cord Foundation and Mediware, Inc. are proud to welcome Dr. Moshe Israeli for our next edition of Share the Science on March 14th, 2017. Share the Science is a free webinar series focused on the cord blood industry and the latest research in this field.  As always, we invite both health professionals and the general public to join us for this enlightening presentation.

Dr. Moshe ISRAELI
from the Rabin Medical Center in Israel
“Stem Cell Donor Search in the Global Village: What Lies Ahead?”

Tuesday, March 14: 1:30 CT/2:30 ET

Free to register. Open to the public.

Register for SHARE THE SCIENCE with Dr. Moshe Israeli: Stem Cell Donor Search in the Global Village

For this edition of Share the Science, Dr. Israeli will explain the challenges of finding a suitable matched donor and the new promise of using cord blood for transplants. He will also explore the growing complexity of global searches and the impact genetics is playing in creating new challenges. Dr. Israeli will discuss:

  • The basics of immunogenetics and the challenges of tissue typing
  • Immunological challenges of a stem cell transplant
  • The process of a global stem cell donor search and, in particular, a cord blood stem cell search
  • How today’s “global village” is creating new challenges for the transplant community

As the director of the tissue typing laboratory of the Beilinson Hospital, Rabin Medical Center in Israel, Dr. Israeli is responsible for all immuno-genetic diagnostic testing of all organ and stem cell transplants carried out by the Clalit Health Services organization in Israel. In addition he serves as the quality manager of the Bedomayich-Chayi public cord blood bank in Jerusalem.

Dr. Israeli has a PhD in transplant immunology from the Bar-Ilan University and has completed a postdoctoral fellowship in the Leiden University Medical Center in the Netherlands. He has presented lectures in multiple international meetings and has received several awards in his field of expertise, such as the J. Marilyn McQueen Award for outstanding scientists on behalf of the American Society for Histocompatibility and Immunogenetics (ASHI), The Wolf Foundation Scholarship for outstanding researchers, and others.

Want to learn more?

Share the Science continues to be a popular series within the cord blood community and beyond. We welcome your input on the series and suggestions for future speakers. Give your feedback here.

powerhouses of science - cord blood research
Previous Share the Science presentations have been archived for your reference. Discover the work of leading scientists and cord blood industry experts through this educational series. View the archive now.

Share the Science is made possible thanks to the generous support of Mediware, Inc.

 

Cord Blood Spotlight at 2017 ISCT Annual Meeting in London

Cord Blood Spotlight at 2017 ISCT Annual Meeting in London

This May, London will welcome the world’s best in the cord blood industry and cellular therapy. Just prior to the 2017 ISCT Annual Meeting, an exclusive 2-day workshop and lecture “Cord Blood Spotlight” will be hosted by FACT, CBA, ISCT, and ASBMT welcoming world-renowned cord blood scientists and transplant physicians.

In the decades since Dr. Eliane Gluckman and her team performed the world’s first cord blood transplant in France, the number of applications for this non-controversial source of stem cells have grown dramatically. Today, cord blood is being used to treat over 80 different diseases.  Since 1988, there have been over 35,000 cord blood transplants worldwide. The industry has grown globally to include a dynamic mix of public, private and hybrid cord blood banks. In particular, research using cord blood for regenerative medicine purposes has continued to evolve in amazing ways. Today, it is not unusual for us to talk about cord blood saving someone from cancer or being used to help a young child with cerebral palsy.

Globally, many of the industry’s players work together helping patients in need crossing public / private barriers as well as international borders. The cord blood industry is unique in that it is not selling a drug but rather enabling parents to help their own families or a stranger in need by storing and processing a valuable, natural medical resource — cord blood. However, while the industry is unique it is not immune to standards. In fact, these standards are even more important given the global nature of the industry and stem cells themselves. Quality assurance is compulsory. Understanding how cord blood is going to be used in the near or distant future is vitally important when considering which processes and standards to apply during the collection and storage process.

The 2-Day “Cord Blood Spotlight” has been designed with these challenges in mind.  The purpose of this meeting is to provide insight on cord blood banking standards and foster a pro-active approach to improving the quality of cord blood banking worldwide. This 2-day event will provide cord blood banks from the globe an opportunity to speak one-on-one with cord blood scientists and transplant physicians to better understand why certain processes are preferred and how banks could potentially increase the number of transplants completed by strengthening quality assurance.

Click here to REGISTER for “Cord Blood Spotlight”

Below is an overview of the 2-day program being proposed by FACT, CBA, ISCT and ASBMT:

cord blood spotlight ISCT London

2017 ISCT Annual Meetings: Cord Blood Spotlight

Click here for more info on the 2017 ISCT Annual Meetings.

Share the Science: Dr. Charles Cox Jr – Cellular Therapies for Neurological Injuries

Share the Science: Dr. Charles Cox Jr – Cellular Therapies for Neurological Injuries

Save the Cord Foundation and Mediware, Inc. are pleased to welcome Dr. Charles Cox, Jr as a featured speaker on “Share the Science.”  Dr. Cox will be speaking about cellular therapies for neurological injuries, preclinical and early clinical trials occurring in the field, and future outlooks.

Dr. Cox is the George and Cynthia Mitchell Distinguished Chair in Neurosciences and directs the Pediatric Surgical Translational Laboratories and Pediatric Program in Regenerative Medicine at the UTHealth Medical School. He also directs the Pediatric Trauma Program at the UTHealth Medical School/Children’s Memorial Hermann Hospital in the Texas Medical Center.

Recently, Dr. Cox completed the first acute, autologous cell therapy treatment Phase I study for traumatic brain injury in children (aged 5-14) in a collaborative effort between leading institutions in the Texas Medical Center including The University of Texas Medical School at Houston, Memorial Hermann Children’s Hospital, MD Anderson Children’s Cancer Hospital, and The Center for Cell and Gene Therapy (CAGT) at Baylor College of Medicine.  The study has evolved to include analysis of the use of cord blood stem cells in treating traumatic brain injury and the role of heterologous cellular therapies.

It is with great pleasure that we welcome Dr. Cox to “Share the Science” where he will go into great detail about various stem and progenitor cellular therapies as potential treatments for neurological injuries, the differences between these many cell types, preclinical and early clinical trials occurring in the field, and future outlooks.

Dr. Charles Cox, Jr
from the UTHealth Medical School and
Children’s Memorial Hermann Hospital
will present
“Cellular Therapies for Neurological Injuries”
Recorded Friday, February 3rd – 11am Central Time
View the Recorded Webinar: FREE and Open to the Public

View the RECORDED WEBINAR now for SHARE THE SCIENCE with Dr. Charles Cox Jr

As an introduction to this webinar, we recommend viewing the short interview we did with Dr. Cox last year during the Perinatal Stem Cell Conference where he emphasized the role of cord blood in regenerative medicine (read the full article here).

Attendees of this webinar will have the opportunity to learn about:

  • Historical perspective of the development of preclinical data in the field
  • How to differentiate between various cell types
  • Benefits of potential pleiotropic mechanisms of action
  • How to be a better critical reviewer of the literature

Attendees will also be invited to ask Dr. Cox questions live during this event.

 * * * *

We wish to thank Dr. Charles Cox Jr. for volunteering his time to speak on
Share the Science and sharing his valuable insight on cellular therapies for neurological injuries.

We also wish to thank our generous sponsors, Mediware Inc., who continue
to support cord blood education through our “Share the Science” series.

Get Involved. Join the #cordbloodmovement!

Save the Cord Foundation thrives on passionate people like yourself who are eager to share what they have learned about cord blood with others. Whether you are a teacher, parent, doctor, nurse or researcher. . . you can make a difference! Join us on social media and share your favorite article or program from Save the Cord Foundation. Give us a shout when you do and we will let the world know that you are doing your part!

Click here to get involved and spread the word.

Cord blood saves lives. Let’s stop throwing it away. 

Share the Science LIVE at BMT Tandem:  Dr. Miguel-Angel Perales,  Immune System Reconstitution Post-Transplant

Share the Science LIVE at BMT Tandem: Dr. Miguel-Angel Perales, Immune System Reconstitution Post-Transplant

Immune system reconstitution post-transplant is a major challenge for cancer patients. Dr. Miguel-Angel Perales is an expert in this field.  At BMT Tandem 2017, Dr. Perales spoke live as part of our on-going #SHARETHESCIENCE series.

Save the Cord Foundation and Mediware, Inc. welcomed Dr. Miguel-Angel Perales as our featured speaker this year at BMT Tandem in Miami, Florida. Dr. Perales presented “Immune Reconstitution after Stem Cell Transplant: Challenges and Opportunities.”  This event was free and open to the public.

NOW AVAILABLE:  RECORDING FROM THIS LIVE EVENT. CLICK HERE.

We encourage health professionals and current medical students in the area to attend. If you have a family member about to undergo a stem cell transplant, you may also find this presentation of particular interest. Join us by reserving your place now (free).

Immune reconstitution following a stem cell transplant is crucial for patients. Allogeneic hematopoietic stem cell transplant (HCT) is an established treatment for hematologic malignancies. However, it is associated with significant adverse events, including infection, relapse, and graft-versus-host disease (GVHD). An important variable that may affect these outcomes is the recovery of the immune system after transplant.  Surprisingly, there are no FDA approved methods or strategies for immune reconstitution. Several preclinical and clinical studies have identified promising therapeutic strategies for immune regeneration.

In this live presentation, Dr. Perales will review immune reconstitution following HCT, with a particular emphasis on factors that contribute to delayed immune recovery post transplant, including graft source, and the clinical consequences. He will also discuss current clinical and research assays to monitor post-HCT immune recovery and highlight some of the potential strategies that are currently under investigation to enhance immune recovery in HCT recipients.

Dr. Miguel-Angel Perales
from Memorial Sloan Kettering Cancer Center

presents
“Immune Reconstitution after Stem Cell Transplantation:
Challenges and Opportunities”

LIVE at BMT TANDEM 2017
Gaylord Palms Convention Center, Room: Miami 1
Thursday, February 23rd, 2017
7:00-8:30 am Eastern Time
Free to register. Open to the public.

VIEW the recording of this LIVE event at BMT Tandem 2017

As a leading researcher, Dr. Miguel-Angel Perales  is the deputy chief of the Adult Bone Marrow Transplantation Service and director of the Adult Bone Marrow Transplant Fellowship Program at Memorial Sloan Kettering Cancer Center in New York. He has more than 130 publications, including peer-reviewed articles, position papers, guidelines, book chapters, editorials, and invited reviews.

In addition to his many accolades, Dr. Perales a member of the board of directors of Be The Match (National Marrow Donor Program – NMDP) and serves on committees for several organizations, including the American Society for Blood and Marrow Transplantation (ASBMT), the American Society of Hematology (ASH), the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), the Center for International Blood and Marrow Transplant Research (CIBMTR), and the Alliance for Clinical Trials in Oncology.

  *  *  *

We wish to thank Dr. Perales for volunteering his time to speak on
Share the Science and sharing his valuable insight stem cell transplants.

We also wish to thank our generous sponsors, Mediware Inc., who continue
to support cord blood education through our “Share the Science” series.

Discover the full Share the Science series and view archived webinars highlighting the latest cord blood research.

powerhouses of science - cord blood research

Share the Science: Dr. Colleen Delaney: Applications for Expanded Cord Blood Progenitor Cells

Share the Science: Dr. Colleen Delaney: Applications for Expanded Cord Blood Progenitor Cells

As part of our on-going #SHARETHESCIENCE series, Save the Cord Foundation and Mediware, Inc. are proud to welcome Dr. Colleen Delaney who will speak about the possible clinical applications of expanded cord blood progenitor cells.

As the scientific founder and chief medical officer of Nohla Therapeutics, Inc., Dr. Delaney’s research interests focus on the role of the Notch signaling pathway in hematopoietic stem cell regulation and ex-vivo expansion of umbilical cord blood stem and progenitor cells for clinical applications.

The success of her research led to the establishment of Nohla which is a cellular therapy company focused on developing off-the-shelf, universal donor therapies that require no HLA matching. Her group has developed a novel and clinically feasible method for the ex vivo expansion of cord blood derived hematopoietic stem and progenitor cells in the presence of Notch ligands. This work was translated into a novel pilot study investigating the use of ex vivo expanded cord blood progenitors to augment conventional cord blood transplantation.

She has since extended this work to investigate the potential of cryopreserved, non-HLA matched “off-the-shelf” ex vivo expanded cord blood progenitor cells to provide rapid but transient myeloid reconstitution in the setting of cord blood transplant and following dose-intensive chemotherapy.

For this Share the Science webinar, Dr. Delaney discusses methods for expanding cord blood stem and progenitor cells, and the clinical application of these cells for cord blood transplant and chemotherapy-induced neutropenia.

Dr. Colleen Delaney from NoHLA Therapeutics
presents
“Clinical Applications for Expanded Cord Blood Progenitor Cells”
RECORDED:  Wednesday, December 14th: Noon – 1 p.m. central time
Webinar:  Free to register. Open to the public.

VIEW this recorded SHARE THE SCIENCE webinar featuring Dr. Colleen Delaney: Clinical Applications of Expanded Cord Blood Progenitor Cells

Cord blood is an effective and widely used source of stem cells for patients undergoing hematopoietic stem cell transplant for hematologic malignancies. While cord blood offers some distinct advantages over conventional stem cell sources, delayed engraftment due to the low cell dose available in each unit continues to be a challenge in the transplant setting. This webinar will cover development and clinical translation of methodologies for the ex vivo expansion of cord blood stem and progenitor cells.

Dr. Delaney will also discuss the clinical use of expanded cord blood progenitors, which has been shown to be safe in the settings of hematopoietic transplant and dose-intensive chemotherapy. In the cord blood transplant setting, use of these expanded cells has been shown to reduce time to neutrophil and platelet recovery as well as being associated with less severe acute GVHD. In the setting of chemotherapy-induced neutropenia, expanded cells have been shown to decrease the rate of documented infection.

  *  *  *

We wish to thank Dr. Delaney for volunteering her time to speak on Share the Science and sharing her valuable insight on cord blood.

We also wish to thank our generous sponsors, Mediware Inc., who continue to support cord blood education through our “Share the Science” series.

Discover the full Share the Science series and view archived webinars highlighting the latest cord blood research.

powerhouses of science - cord blood research

Share the Science: Improve Operating Costs & Maximize Potential of Cord Blood – Linda Peltier, PhD

Share the Science: Improve Operating Costs & Maximize Potential of Cord Blood – Linda Peltier, PhD

Cord blood banking is expensive.  Preserving cord blood is a process that depends on highly skilled personnel and very sophisticated equipment. Operating costs are high. Upfront investments for both public and private are significant.

In recent years, the increase in regulations have created new challenges for those running public and private banks. Public banks are counting every penny while trying to offer the option to donate cord blood to as many parents as possible. Some private banks have pursued hybrid models in order to serve parents who want to donate as well as those who wish to privately bank. The hybrid model presents both challenges and opportunities when considering operating costs. Meanwhile, private banks continue to fight rising fierce competition which, in turn, forces them to keep prices as low as possible.

The main question on everyone’s mind is “How can we do this better?”

  • Can we lower operating costs?
  • How can we recover costs and still help the greater good?
  • Can we do something useful with cord blood donations that do not meet the new criteria imposed by public registries?
  • Can we take advantage of new operating methods and new transplant methods?

Share the Science welcomes Linda Peltier, Ph.D. from McGill University who will share her expertise on improving operating costs for cord blood banks and how to maximize the potential of cord blood collections.  With over 35 years of experience in the different healthcare fields, Peltier has become an authority in clinical and laboratory quality assurance. For the past 12 years, she has specialized in cord blood banking and stem cell processing. (Learn more about the cord blood bank at McGill University Health Centre here.)

Share the Science with Linda Peltier, PhD
“How to Potentialize Donations to Cord Blood Banks”
RECORDED:  Friday, December 2nd, 11 a.m. – 12 p.m, Central Time
Free webinar. Open to the public.

VIEW this recorded webinar now featuring Linda Peltier discussing: How to Potentialize Donations at Cord Blood Banks

In this free webinar, Peltier will discuss how public cord blood banks were initially established to store optimal units for allogeneic hematopoietic stem cell transplant (HSCT). Compliance with new regulations and transplant physician requests for an increased number of cells per cord blood unit (CBU) increased the processing costs to a point that some public CBBs had to merge or shut down. The current operational model must be modified. Product diversification and better use of each CBU is one approach that could improve the CBB cost recovery model.

Peltier will discuss ways to recover cord blood and tissue components for a better operational cost. Her analysis is based on 1607 CBUs collected by the McGill University Health Centre Clinical Research Cord Blood Bank (MUHC CRCBB). McGill’s bank was able to recover more than 85% of units rejected by the public bank and calculated that making available cord blood plasma for MSC culture could double the revenue of the bank.

This webinar promises to be beneficial to the management teams of both public and private banks. There is opportunity here, especially for those banks who adhere to the highest standards. Techniques taught in this webinar could help put your cord blood bank ahead of the competition while helping the industry as a whole.

 *  *  *

We wish to express our sincere thanks to Linda Peltier for sharing her expertise and insight
on improving operational costs for cord blood banks.

Mediware_Corporate (1)We also wish to thank our generous sponsors, Mediware Inc., who continue to support cord blood education through our “Share the Science” series.

 

 

Share the Science:  Cord Blood to Help People with Spinal Cord Injury, Dr. Wise Young at AABB

Share the Science: Cord Blood to Help People with Spinal Cord Injury, Dr. Wise Young at AABB

Every year it is estimated that there are 12,000 spinal cord injuries in the US alone (http://www.ninds.nih.gov/disorders/sci/detail_sci.htm). These are life changing injuries for which there is currently no cure. Long term care of patients suffering from spinal cord injury is not only extremely expensive, it is emotionally and physically challenging in ways few could ever understand.  Cord blood could provide hope to those who so desperately need it.

Special LIVE EVENT during 2016 AABB Conference in Orlando, Florida
SHARE THE SCIENCE

featuring

Wise Young, MD, Phd
“Cord Blood Therapies as Potential Treatments for People with Chronic Spinal Cord Injury
Orange County Convention Center, room W224GH Orlando, FL
Monday, October 24, 2016
7:00 – 8:15 a.m. eastern time

NOTE:  This was a special LIVE event held during the
2016 AABB Conference in Orlando, Florida. This presentation was not recorded.

View the archive of Share the Science webinars.

Dr. Wise Young, M.D., Ph.D., Distinguished Professor, founding director of the W.M. Keck Center for Collaborative Neuroscience and a distinguished professor, is recognized as one of the world’s outstanding neuroscientists.

His accolades are many yet what makes him a leading researcher in the cord blood industry is his commitment to bringing treatments to people with spinal cord Injuries. He built and trained a 25 center clinical trial network in China, Taiwan, and Hong Kong, where human clinical trials using umbilical cord blood mononuclear cells and lithium are underway. In the initial results from the phase II trial in Kunming, China, 75% of the participants (15 out of 20) recovered walking with a rolling walker. He is establishing clinical trial networks in the United States, Norway, and India. Phase IIB trials started in 2015, and phase III trials are getting underway this year.

We are truly honored to have Dr. Young join us for this special edition of “Share the Science” during the 2016 AABB Conference.

Attendees of this live “Share the Science” presentation will hear Dr. Young give details on his groundbreaking research “Cord Blood Therapies as Potential Treatments for People with Chronic Spinal Cord Injury.”  Dr. Young will begin with a discussion about the rationale for his work. . .

“In the past decade, hundreds of laboratories have reported that UCB cells, particularly UCB mononuclear cells (UCBMNC), have beneficial effects on a variety of conditions, including cerebral palsy, stroke, and spinal cord injury. Several groups have done clinical trials transplanting UCBMNC into the brain and spinal cords of patients, suggesting that the therapies are safe and possibly beneficial. We sought to test the safety and efficacy of UCBMNC transplanted into people with chronic complete spinal cord injury. In addition, because animal studies suggest that lithium stimulates UCBMNC to grow and to produce growth factors that stimulate regeneration, we wanted to assess the effects of a 6-week course of oral lithium carbonate given to patients after transplant of UCBMNC.”

Dr. Young will also discuss in detail:

  • Why exercise is necessary but not sufficient for recovery
  • How people can recover even after chronic complete spinal cord injury
  • Skepticism of claims that intrathecal administration of UCBMNC will be effective for chronic spinal cord injury, particularly without intensive rehabilitation

Attendees of this presentation will learn about various clinical applications using UCBMNC to treat spinal cord injury, results of these trials by Dr. Young and how people can recover from chronic spinal injury.

 *  *  *

We wish to thank Dr. Young for participating in “Share the Science” and sharing his valuable insight on using cord blood to potentially treat spinal cord injuries.

Mediware_Corporate (1)We also wish to thank our generous sponsors, Mediware Inc., who continue to support cord blood education through our “Share the Science” series.

 

Can We Prevent or Cure Diabetes with Cord Blood? The CoRD Study

Can We Prevent or Cure Diabetes with Cord Blood? The CoRD Study

Type 1 diabetes is one of the most common chronic diseases of childhood, affecting around 1 in 500 children.  The world is desperate for a cure and many scientists feel that cord blood could be the key to potentially eradicating this horrible disease. The CoRD Study in Australia, led by Dr. Maria Craig, hopes to provide answers.

UPDATED: To view the webinar recorded August 17th, 2016, please follow the link below.

Dr. Maria Craig, professor of paediatric endocrinology, the University of Sydney and Sydney Children’s Hospital Network, recently joined us on Share the Science to discuss the CoRD study (Cord blood Reinfusion in Diabetes). This pioneering study represents a world-first in using cord blood to potentially treat or even cure Type 1 diabetes.

Visit the official website for this clinical trial using cord blood to treat diabetes.

Type 1 diabetes results from the destruction of the insulin-producing cells in the pancreas by the body’s immune system. It appears that there is an imbalance between certain types of immune cells and ‘good’ immune cells called regulatory T cells, which are important in controlling the immune system.

During this webinar, Dr. Craig helps us in understanding more about the immune system in children at risk of developing type 1 diabetes as well as the potential for preventing this disease.

Share the Science with Dr. Maria Craig
“Can we prevent or cure Type 1 Diabetes with cord blood?”
Wednesday, August 17th, 4:00 – 5:00 p.m. Central Time
Free webinar. Open to the public. 

View the RECORDED WEBINAR with Dr. Maria Craig who discusses the CoRD Study on diabetes.

Cord blood contains a diverse mixture of cells. It is a particularly rich source of stem cells that have the ability to develop into many different blood cell types, creating the blood and immune system. Cord blood is also a source of other types of stem cells as well regulatory T-cells, which may have potential for treating immune disorders. Due to their flexibility and diversity, the cells found in cord blood may be effective in the treatment of many other diseases, including heart disease, stroke, diabetes, and neurological disorders such as cerebral palsy.

In Australia, Dr. Craig and her team are undertaking a world-first study, the CoRD study, to assess whether the unique cells found in cord blood can actually stop the immune destruction in the pancreas and protect a child from developing the disease. The study is aimed at high-risk children (those who have a close relative with type 1 diabetes) who have their cord blood stored in a cord blood bank.

The pilot study involves two phases:

  • Screening – in which a child is tested for diabetes autoantibodies (early markers of diabetes)
  • Treatment and follow-up – where eligible children who are at very high risk of developing diabetes receive an infusion of their own cord blood and then are followed up.

Dr. Craig and her team believe the study will help us to understand more about the immune system in children at risk of developing diabetes and may actually help find ways to prevent this lifelong disease.  The CoRD study is being funded by a grant from Australia’s largest private cord blood bank, Cell Care Australia.


A special thank you to our friends at
Mediware Information Systems

who have helped make this webinar possible through their generous support.


Are you enjoying our Share the Science series? 

Give a $10 Donation!

Thank you for joining us each time for a new and exciting discussion with a leading cord blood expert.

We never charge a fee for our programs and we want to keep it that way.

At Save the Cord Foundation, we are serious about cord blood education. Help us to keep programs like Share the Science going strong and keep the cord blood industry growing strong, together.

Make a tax-deductible donation today!

Thank you.

 


CLICK HERE TO VIEW OTHER WEBINARS FROM THE SHARE THE SCIENCE ARCHIVE

About Save the Cord Foundation

Save the Cord Foundation, a 501c3 non-profit organization, was established to promote awareness of the life-saving benefits of cord blood based on unbiased and factual information. The Foundation educates parents, health professionals and the general public about the need to preserve this valuable medical resource while providing information on both public cord blood donation programs and family cord blood banks worldwide.

Support Save the Cord Foundation

Our mission depends on supporters like you. Please support our cause by making a donation or promoting our website and message where you can. We appreciate all the support!
(We NEVER ask for cash donations. Online donations are easier and safer. Thank you.)

© 2016 Save The Cord Foundation - All Rights Reserved · Powered By: Joker Media